ライフサイエンスコーパス: chelonae

1 be M. abscessus and 29 were identified as M. chelonae.

2 ily identify isolates of M. abscessus and M. chelonae.

3 submitted as M. abscessus was found to be M. chelonae.

4 an incorrect identification as Mycobacterium chelonae.

5 r distinguishing between M. abscessus and M. chelonae.

6 en Mycobacterium abscessus and Mycobacterium chelonae.

7 Mycobacterium sp. most closely resembling M. chelonae.

8 age altered drug resistance in Mycobacterium chelonae.

9 ycobacterium abscessus but not Mycobacterium chelonae.

10 mycobacteria including M. llatzerense and M. chelonae.

11 , M. nonchromogenicum (11 of 11), and the M. chelonae-abscessus complex (21 of 21).

12 Members of the Mycobacterium chelonae-abscessus complex (MCAC) are close to the mycob

13 against clarithromycin; M. abscessus and M. chelonae against the aminoglycosides; and all three spec

14 ug/mL) in clinical isolates of Mycobacterium chelonae, an RGM species not previously known to contain

15 d in 100% correlation with 25 isolates of M. chelonae and 25 isolates of M. abscessus.

16 ze of M. immunogenum varied from those of M. chelonae and M. abscessus.

17 tial 16S rRNA gene sequencing to identify M. chelonae and M. abscessus.

18 ld only differentiate M. immunogenum from M. chelonae and M. abscessus.

19 acin, clarithromycin, tobramycin (only in M. chelonae), and cefoxitin (only in M. abscessus) was show

20 complex (MCC), including M. immunogenum, M. chelonae, and M. abscessus, have been associated with no

21 test species, Mycobacterium immunogenum, M. chelonae, and M. abscessus, showed various susceptibilit

22 ended incubation may not be necessary for M. chelonae, and the erm(41) genotype is a useful adjunct f

23 Mycobacterium abscessus and Mycobacterium chelonae are two closely related species that are often

24 g mycobacteria suspected to be Mycobacterium chelonae at a hospital in New Jersey.

25 Members of the Mycobacterium chelonae complex (MCC), including M. immunogenum, M. che

26 arrow-spectrum activity against M. abscessus-chelonae complex species.

27 ly, uncapped LAM purified from Mycobacterium chelonae did not induce IL-12 secretion or apoptosis.

28 not harbor functional erm genes and, like M. chelonae, do not require extended clarithromycin suscept

29 . smegmatis, primarily secrete Ndk, while M. chelonae does not appear to secrete either of these two

30 istance and that isolates of M. abscessus/M. chelonae from CF patients are more likely than those fro

31 equencing does not distinguish Mycobacterium chelonae from M. abscessus.

32 . marinum, M. scrofulaceum, M. avium, and M. chelonae grew at pH 6.0 in an unrestricted manner.

33 The most frequent species isolated was M. chelonae group (10 patients).

34 plex, 3 M. kansasii, 4 M. gordonae, and 5 M. chelonae group (all were M. abscessus) isolates.

35 M. avium, M. intracellulare, M. kansasii, M. chelonae group, M. gordonae, M. xenopi, and M. scrofulac

36 Twenty-two isolates of M. chelonae had tedizolid and linezolid MIC90s of 2 mug/ml

37 The species isolated were Mycobacterium chelonae in 14 patients (73.7%), M fortuitum in 3 patien

38 case of disseminated cutaneous Mycobacterium chelonae infection in a patient with head and neck cance

39 case of refractory cutaneous disseminated M. chelonae infection in a patient with seronegative arthri

40 We report 3 cases of Mycobacterium chelonae infections after bee venom acupuncture.

41 Multidrug-resistant M. chelonae infections present a challenge for treatment, a

42 Mycobacterium chelonae infections should be included in the differenti

43 Mycobacterium chelonae is a rare cause of chronic disseminated cutaneo

44 nts, showed abnormalities in all 17, with M. chelonae isolated from 14 and confirmed by means of DNA

45 41) sequencing of 285 M. abscessus and 45 M. chelonae isolates was compared to 14-day susceptibility;

46 bacterium abscessus, and three Mycobacterium chelonae isolates) were tested against amikacin, cefoxit

47 al of 82 isolates (58 M. abscessus and 24 M. chelonae isolates) were tested blindly against 15 antimi

48 e of a detectable erm gene in isolates of M. chelonae, M. senegalense, and M. peregrinum and a nonfun

49 rRNA gene sequencing (26 isolates of the M. chelonae-M. abscessus complex and 64 remaining isolates,

50 ex (MTC), the M. avium complex (MAC), the M. chelonae-M. abscessus group (MCAG), the M. fortuitum gro

51 m isolates previously identified as being M. chelonae/M. abscessus and identified M. massiliense from

52 that is indistinguishable from Mycobacterium chelonae/M. abscessus by partial 16S rRNA gene sequencin

53 matis, Mycobacterium gordonae, Mycobacterium chelonae, Mycobacterium fortuitum, and Mycobacterium scr

54 bacterium avium (n = 20, 44%), Mycobacterium chelonae (n = 7, 16%), and Mycobacterium fortuitum (n =

55 ipenem, sulfamethoxazole, and tobramycin (M. chelonae only) in four laboratories.

56 Mycobacterium chelonae should be considered in the differential diagno

57 outbreak of tattoo-associated Mycobacterium chelonae skin and soft-tissue infections in Rochester, N

58 ify 75 isolates as either M. abscessus or M. chelonae that were originally submitted for drug suscept

59 ycobacterium salmoniphilum and Mycobacterium chelonae type strains, seven M. salmoniphilum isolates,

60 In addition, Mycobacterium chelonae was isolated from 5 unopened bottles of graywas

61 Eight isolates originally submitted as M. chelonae were identified as M. abscessus, and one isolat

62 or =16 microg/ml), while all isolates of M. chelonae were susceptible to this drug (MIC of < or = 4

63 terium abscessus, and three of Mycobacterium chelonae) were tested against amikacin, cefoxitin, cipro

64 Another 2 skin specimens grew Mycobacterium chelonae, which also grew from a bottle of graywash ink